The effect of Melatonin on the disability of multiple sclerosis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017072520258N55

Enrollment

Registered

2017-08-07

Start date

2015-04-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: We prescribe 3 milligram Melatonin every night for 12 weeks. Intervention 2: In control group: We prescribe placebo for 12 weeks.

Treatment - Drugs

Intervention group: We prescribe 3 milligram Melatonin every night for 12 weeks.

In control group: We prescribe placebo for 12 weeks.

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: multiple sclerosis with Mc.donald score; 18 to 50 years; ?expanded disability ?status scale (EDSS) 0 to 5.5? Exclusion criteria: pregnancy; ?use pulse Corticosteroids drug in 6 months ago; side effect of drug; lack of ?routine monitoring of ?patients. ?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
?disability. Timepoint: before treatment and 12 ?weeks after treatment. Method of measurement: Disability Status Scale (EDSS)?.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Aliakbar Maleki rad

Arak University of Medical Sciences

malekirad@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026